Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode how TriSalus funds its Pressure Enabled Drug Delivery (PEDD) platform or when nelitolimod might reach pivotal trials? Biotech filings can span hundreds of pages packed with medical jargon and accounting footnotes. Our SEC hub turns TriSalus Life Sciences SEC filings explained simply into a reality—no more hunting for pipeline costs or FDA correspondence across scattered documents.
Stock Titan’s AI reads every TriSalus Life Sciences quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the moment they hit EDGAR. It surfaces answers to real investor questions like “understanding TriSalus Life Sciences SEC documents with AI” or “What’s in the TriSalus Life Sciences proxy statement executive compensation?” You’ll also see real-time alerts for TriSalus Life Sciences Form 4 insider transactions real-time, letting you track TriSalus Life Sciences executive stock transactions Form 4 alongside AI-powered context—was that purchase timed before a Phase 2 data read-out?
Need practical insights fast? Our dashboard pulls out exactly where the 10-K details PEDD revenue, highlights cash-runway notes in the 10-Q, and flags 8-K disclosures on device approvals. Key features include:
- AI summaries that condense complex oncology language into plain English
- Instant updates on TriSalus Life Sciences insider trading Form 4 transactions
- Side-by-side TriSalus Life Sciences earnings report filing analysis for trend spotting
Whether you’re vetting immuno-oncology pipelines or comparing R&D burn rates, our platform delivers the full story behind every document—so you can act on data, not guesswork.
TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 on 27-Jun-2025 for director Arjun J. Desai. On 12-Jun-2025 Desai received a grant of 15,000 non-qualified stock options at an exercise price of $5.50 per share. The options will fully vest on the earlier of (i) 12-Jun-2026 or (ii) the company’s next annual shareholder meeting, subject to continued service. They expire on 11-Jun-2035. After this grant, Desai beneficially owns 65,000 derivative securities; no common shares were acquired or sold, and ownership remains direct. The filing represents routine director compensation and does not disclose any open-market transactions.
Form 4 filing overview: On June 12 2025, TriSalus Life Sciences, Inc. (TLSI) granted Director Gary B. Gordon a non-qualified stock option covering 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on June 11 2035.
Vesting terms: The option will become fully vested on the earlier of (i) the one-year anniversary of the grant date (June 12 2026) or (ii) the date of TLSI’s next annual stockholder meeting, provided Mr. Gordon remains in service through such date.
Post-transaction ownership: Following the grant, Mr. Gordon beneficially owns 56,250 derivative securities (stock options) in TLSI, all held directly. No changes in non-derivative share ownership were reported.
Key takeaways for investors: • This is a routine incentive grant to a board member, aligning director compensation with shareholder interests.
• No open-market purchases or sales were disclosed; therefore, the filing does not signal immediate sentiment regarding TLSI’s current share price.
• The grant size is modest and is unlikely to have a material impact on the company’s capitalization or insider ownership structure.
Form 4 filing overview: On 06/12/2025, TriSalus Life Sciences, Inc. (TLSI) director Kerry R. Hicks was granted a non-qualified stock option for 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on 06/11/2035 and will vest in full on the earlier of 06/12/2026 or the company’s next annual shareholder meeting, subject to continued board service.
Following the grant, Mr. Hicks now beneficially owns 89,222 derivative securities (principally stock options). The filing indicates direct ownership; no indirect holdings were reported. No purchases or sales of common stock occurred, and the filing does not disclose any change to Mr. Hicks’ non-derivative share count.
The transaction was coded “A” (acquisition), routine for director compensation, and was not executed under a Rule 10b5-1 plan. Because the filing relates only to an option grant—without an accompanying open-market trade—its immediate market impact is typically limited. Nevertheless, investors may view the award as modest alignment of director incentives with shareholder interests through long-dated equity compensation.
TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 reporting a routine equity award to director Sean Murphy. On 06/12/2025 Mr. Murphy was granted 15,000 non-qualified stock options with an exercise price of $5.50 per share. The award will fully vest on the earlier of one year from grant or the company’s next annual shareholder meeting, contingent on his continued service. The options expire on 06/11/2035. After the grant, the director beneficially owns 554,681 derivative securities (options) in aggregate. No shares of common stock were bought or sold; this filing solely reflects the incentive grant and therefore does not immediately affect the public float or insider ownership percentage.
FAQ
What is the current stock price of TriSalus Life Sciences (TLSI)?
What is the market cap of TriSalus Life Sciences (TLSI)?
